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Abstract: 
Histone Deacetylase (HDAC) inhibitors represent a budding class of targeted anti-cancer agents. This structurally diverse 
group of molecules can induce growth arrest, differentiation, apoptosis, and autophagocytic cell death of cancer cells. Of the 
different classes of HDAC the class I and Class II are considered the main targets for cancer. For the two classes of HDAC, 
only a few compounds have emerged as preferential inhibitors and even fewer are able to discriminate efficiently among 
HDACs in the same class. This limitation has diminutive relevance to the use of HDAC inhibitors as potential anti-tumor 
drugs. Hence, the four HDACs of class I was modeled and about twelve known inhibitors which are currently under the 
phase I/II trials were docked using an efficient shape-based search algorithm and the AScore scoring function, to each of the 
class I HDAC members in order to identify the inhibitor or group with better pharmacological action. The molecular 
descriptors study and the drug score, drug likeness prediction helped in the identification of potential compounds targeting 
specific enzymes of HDAC family. The ranking of various groups of ligands helped in the identification of potential groups 
and better compound that can better target class I HDAC in an effective way. 
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Abbreviations: HDAC = histone deacetylase, HDACi = histone deacetylase inhibitor, TPSA = total polar surface area, SCR 
= structurally conserved region. 
 
Background: 
Cancer is a generic term for a group of over 100 chronic 
diseases, which can affect any part of the body. A defining 
feature of cancer is the rapid creation of abnormal cells, 
which grow beyond their usual boundary and can invade 
adjoining parts of the body. The cells may also spread to 
other organs, a process referred to as metastasis. It is 
expected that the Cancer incidence would have a steady 
increase to 15 million new cases in the year 2020 [1]. 
Thus, the challenge of developing a novel method to face 
the impending problem is becoming more significant.  
 
HDAC, Histone Deacetylase, is especially known to play 
an important role in carcinogenesis. The enzyme has been 
considered a target molecule for cancer therapy [2]. The 
members of the classical HDAC family fall into two 
different phylogenetic classes, namely class I and class II 
[3, 4]. Deacetylation is a process that removes acetyl group 
from the histone tails, causing the histones to wrap more 
tightly around the DNA and interfering with the 
transcription of genes by blocking access by transcription 
factors. The overall result of deacetylation is a global (non-
specific) reduction in the gene expression. Therefore, the 
inhibition of HDAC activity by a specific inhibitor induces 
growth arrest, differentiation, and apoptosis of transformed 
or several cancer cells. It is this versatility that makes the 
discovery and development of specific HDAC inhibitors 
such a tempting prospect in cancer research.  
 
The aim of this work is to compare the HDAC-I enzyme 
inhibitors that are already in the Phase I/II trials based on 
their pharmacological and ADME (Absorption, 
Distribution, Metabolism and Excretion) and rank them 
accordingly to identify the inhibitor(s) group specific for 
the different enzymes of HDAC-I with better binding 
affinity and better pharmacological properties. Since, no 
theoretical works have been carried out in identifying the 
properties and specificity we intend to identify the group 
that could act as potential binding inhibitors. 
 
Methodology: 
Molecular modeling 
Homology modeling of the three dimensional structure of 
class I Histone Deacetylase (HDAC 1,2,3&8) was carried 
out using the Modeller9v2 [5]. The template used for the 
comparative modeling was PDB ID-‘1T64’ (Crystal 
Structure of human HDAC8 complexed with Trichostatin 
A).The class I HDAC shows close similarity in their 
sequence and hence the structure of HDAC8 was used as 
template for the modeling of the class I Histone 
deacetylase. The SCRs (Structurally Conserved Regions), 
structurally variable regions, N-terminal and C-termini of 
reference structure was assigned to the target sequence 
based on the satisfactory spatial restraints. Thus, the initial 
models of the Class I HDAC enzymes were generated. The Bioinformation by Biomedical Informatics Publishing Group                          open access 
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energy minimization was carried out using the SPDBV [6] 
and the refined structure for all four HDAC-I enzymes 
were obtained. 
 
The Histone Deacetylase Inhibitor (HDACi) structures 
were drawn using the ACD Chemsketch11.0 [7]  which 
offers functionalities like structure cleaning, optimization 
etc.,. About 12 known HDACi (Figure 1) from different 
groups such as hydroxamic acid derivatives, benzamide 
derivatives, cyclic tetrapeptides and short chain fatty acids 
[2, 8, 9] were taken into account for the study. 
 
 
Active site prediction 
The active sites of the four class I HDAC were identified 
using the Q-SiteFinder [10]. The Q-SiteFinder works by 
binding hydrophobic (CH3) probes to the protein, and 
finding clusters of probes with the most favorable binding 
energy. These clusters are placed in rank order of the 
likelihood of being a binding site according to the sum 
total binding energies for each cluster. The higher cavity 
cluster considered and the residues around the cluster were 
identified as the binding residues using the 
SwissPDBViewer. 
 
 
Figure 1:  2D structure of different class of compounds with HDACi activity that is currently in Phase I/II clinical trials. 
1a-1g. Hydroxamic acid derivatives; 1h. Benzamide; 1i. Cyclic Peptide; 1j-1l. Short chain fatty acid derivatives. 
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Figure 2: Structure showing a bound Hydroxamic acid derivative, TSA with HDAC 8. 
 
Docking 
Molecular docking and virtual screening based on 
molecular docking have become an integral part of many 
modern structure-based drug discovery efforts and the 
results are biologically significant. The constructed 
HDACi’s were docked with all the four class I Histone 
deacetylase viz., HDAC1, HDAC2, HDAC3 & HDAC8 
using the Arguslab 4.0.1 [11] which uses a shape-based 
search algorithm . The Docking calculations attempt to 
place Ligands into binding sites. 
 
Molecular descriptors calculation 
Quantitative structure-activity relationships (QSARs) 
correlate the response with molecular properties of 
compounds under interest. Any compound to be considered 
as a lead must possess acceptable scores for all of the 
descriptors. Molinspiration [12]  and Osiris Property 
explorer  [13] were used to calculate twelve descriptors- 
logP, solubility, drug likeliness, polar surface area, 
molecular weight, number of atoms, number of rotatable 
bonds, volume, drug score and number of violations to 
Lipinski’s rule [14] for all the inhibitors taken for the 
analysis (Table in supplementary material). 
 
Toxicity prediction 
Toxicity is defined as a dose-linked unsafe effect of a 
chemical compound on a target life form. Safety issues and 
ADME (Absorption, Distribution, Metabolism and 
Excretion) are major factors in drug failure and they are 
crucial to identify early in the discovery process to reduce 
late-stage attrition. ADME-Tox Box of PharmaAlgorithms 
[15] was used to predict the various toxicity effects such as 
rat LD50, mouse LD50, oral bioavailability, Ames test, 
pKa and ion fraction values. 
 
Discussion:  
The qualities of the homology modeled proteins were 
evaluated using the procheck tool [16]. It estimates the 
stereo-chemical quality of the modeled structures. On 
analysis of the Ramachandran plot, it was observed that in 
the HDAC 1, 2, 3 and 8 around 96.7% of the residues were 
present in the favored regions. The Q-SiteFinder analysis 
produced the ten top most ranked binding sites. The higher 
cavity site was taken as the most favorable site to dock the 
ligands. Each ligand showed different affinities with the 
Class I HDAC family for example SFHA compound 
showed the best affinity with the  HDAC 8   (–10.16 
kcal/mol). Whereas the same compound was found to be 
rank 2 with HDAC1 and HDAC3 (viz. -8.08 kcal/mol and -
9.70 kcal/mol) and rank 3    (-9.87 kcal/mol) with HDAC2. 
Hence, all the ligand compounds were ranked individually 
based on their binding energies with the four HDAC-I 
enzymes in order to identify the more suitable and better 
binding inhibitor group of the HDAC-I. The first five 
ranking inhibitors in each HDAC-I enzyme were 
considered for the analysis and eliminating the common 
ones from the four groups about nine different inhibitors 
were identified from the first five ranks for each HDAC-I 
enzyme. Based on their binding energy ranking TSA and 
SFHA were found to possess better binding affinity to the 
four HDAC-I enzymes because they rank below five in 
each HDAC-I enzyme. 
 
The further descriptor analysis and the toxicity prediction 
helped in the identification of the more suitable inhibitor. 
From  Table 1 (supplementary material), each inhibitor 
were lacking (red color) in at least one or more properties. 
TSA was the only compound that had the acceptable range Bioinformation by Biomedical Informatics Publishing Group                          open access 
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(green color) for drug likeness [17] and also found to 
possess better binding affinity score (Table 1 in 
supplementary material). Drug Score and the Drug-
Likeness are the two properties that are important for 
considering a compound to become a successful drug. 
Though valproic acid had a drug score of 0.61 and drug 
likeness property score of 0.36 it was not appropriate as the 
molecular weight of valproic acid was 116.16 g/mol, a 
value lower than the preferable range of molecular weight 
for drug likeness property (160-480 g/mol) [17]. These 
values were also taken into account to decide the best 
inhibitor (Table 1 in supplementary material). 
 
The ADME-TOX box results showed that the TSA has an 
oral bioavailability of more than 70% i.e., good solubility 
and stability. It acts as a non-substrate and non-inhibitor of 
P-gp. TSA does not undergo significant first-pass 
metabolism [17].  The predicted LD50 values of TSA in 
mouse and rat was found to be 1700mg/kg and 1800mg/kg 
respectively when administered orally. TSA acts as a non-
substrate when checked for the P-glycoprotein substrate 
specificity. 
 
Conclusion: 
The few compounds predicted to inhibit the HDAC family 
are not effective to all forms of HDAC. This analysis 
involves a comparative investigation by the ranking the 
inhibitors based on diverse strategies. It is clear that only 
TSA (a natural compound that can be isolated from the 
metabolites of strains of Streptomyces hygroscopicus) 
satisfied almost all the properties i.e., binding affinity 
scores of TSA in the four HDAC-I enzymes  was -8.99 
kcal/mol, -8.58 kcal/mol, -8.90 kcal/mol & -9.34 kcal/mol 
respectively, the Drug Likeness value (1.24) and drug 
score (0.37) with 70% oral bioavailability and the hydroxyl 
group of these compounds fits well into the active site of 
the target where the zinc  is present [18]   (Figure 2). 
Hence, better hydroxamate derivatives with more potency 
could be developed as potential inhibitors of class-I HDAC 
and valuable anti-cancer-agents. 
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Supplementary material 
 
Descriptors Butyric  acid  CBHA  Depudecin MS-275 Oxamflatin Phenyl 
butyrate 
PXD-
101 
Pyroxa-
mide 
SAHA SFHA  TSA Valproic 
acid 
LogP  0.996  0.305 0.202  2.03 2.187  2.151  2.22 1.396  2.47 3.343  2.68  1.68 
Solubility  -1  -2.56 -1.98  -4.21 -5.17  -2.13  -3.61 -2.53 -3.33 -5.03 -3.26  -1.43 
Molecular weight  88.106  222.2 212.245  376.416 342.376  164.204  318.354 265.313 264.325 286.356 302.374  116.16 
TPSA  37.229  98.652 65.512  106.345 95.495  37.299  95.495 91.316 78.424 61.353 69.635  37.299 
n Atoms  6 16  15 28  24  12 22 19 19 20 22  8 
n ON  2 6  4 7  6  2 6 6 5 4 5  2 
n OHNH  1 4  2 4  3  1 3 3 3 3 2  1 
n Violations  0 0  0 0  0  0 0 0 0 0 0  0 
n Rotatable bonds  2 3  5 7  4  4 5 6 8 5 6  3 
Volume  89.801 190.268  197.632 339.353  288.25  161.45 266.106 251.487 255.644 252.803  293.12  123.19 
Drug score  0.18  0.41 0.39  0.11 0.28  0.47  0.15 0.37 0.35 0.13 0.37  0.61 
Drug Likeness  -3.94  -2.45 -3.52  -14.52 -5.31  -7.06 -7.33 -7.22 -8.87 -3.22  1.24  0.36 
Binding Score of 
HDAC 1,2,3 & 8 
respectively in 
kcal/mol. 
-5.73, -6.47, -
6.63, -6.96 
-7.08,    -
7.77, 
-7.75, 
-7.82 
-5.73, 
-6.64, 
-5.91, 
-6.83 
-7.89, -
10.5, 
-9.92, 
-8.84 
-7.23, 
-11.38, 
-8.88, 
Nil 
-7.55, 
-8.56, 
-8.62, 
-9.0 
-7.50, 
Nil, 
-9.08, 
-7.43 
-6.44, 
-8.17, 
-7.28, 
-6.55 
-6.42, 
-9.02, 
-7.45, 
-9.0 
-8.08, 
-9.87, 
-9.7, 
-10.16 
-8.99, 
-8.58, 
-8.9, 
-9.34 
-7.04, 
-8.48, 
-8.82, 
-9.24 
Table 1: Molecular descriptors value for the twelve HDACi’. 